SCHEMBL2833261

SCHEMBL2833261

Cc1nc(OC2CCOCC2)ccc1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 4/20 0.38
PIK3R1 P27986 1/20 0.38
SYK P43405 1/20 0.38
LRRK2 Q5S007 2/20 0.37
PDE10A Q9Y233 5/20 0.37
HDAC6 Q9UBN7 1/20 0.36
KAT2B Q92831 1/20 0.35
BAZ2B Q9UIF8 1/20 0.35
GRM5 P41594 2/20 0.33
PDE2A O00408 2/20 0.33
CACNB4 O00305 1/20 0.33
CACNA1A O00555 1/20 0.33
CACNA1G O43497 1/20 0.33
CACNG3 O60359 1/20 0.33
CACNA1F O60840 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNB3 P54284 1/20 0.33
CACNA2D1 P54289 1/20 0.33
CACNG7 P62955 1/20 0.33
CACNA1B Q00975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835065 0.91 LRRK2 (0.40) PIK3CALRRK2PDE10AGRM5PDE2A
SCHEMBL19962929 0.89 GPR119 (0.37) PIK3CA
SCHEMBL19963007 0.85 BRD4 (0.36) LRRK2
SCHEMBL19951531 0.85 BRD4 (0.38) LRRK2
SCHEMBL30602452 0.82 LRRK2 (0.37) PIK3CAPIK3R1SYKLRRK2PDE10A
SCHEMBL29130950 0.82 LRRK2 (0.37) PIK3CAPIK3R1SYKLRRK2PDE10A
SCHEMBL15471379 0.79 CACNB4 (0.35) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL30183169 0.79 PDE10A (0.40) PIK3CAPIK3R1SYKLRRK2PDE10A
SCHEMBL16829612 0.78 CYP2D6 (0.43) LRRK2
SCHEMBL22105608 0.78 SLC6A2 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 PIK3CA 3405/4885PIK3R1 4137/4885SYK 1267/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 PIK3CA 3405/4885PIK3R1 4137/4885SYK 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.